Japan Postpones Completion Of Avigan's Clinical Trials Due To Insufficient Data - Reports

TOKYO (Pakistan Point News / Sputnik - 09th June, 2020) Clinical trials of Avigan, a Japanese anti-flu drug which has proven to be effective for treating COVID-19 patients, will not be completed on time due to lack of data as a result of falling coronavirus infection rate, the Kyodo news agency reported on Monday, citing sources in the Fujifilm Holdings Corp. pharmaceutical company.

Avigan was developed by the Fujifilm Toyama Chemical pharmaceutical company six years ago, but due to side effects on the fetus, it was excluded from use by pregnant women and included in a list of drugs to be used in exceptional circumstances with a special order from the government when no available alternatives work.

In March, Japan began conducting clinical trials on 80 coronavirus patients with mild or no coronavirus symptoms. At the moment, Japan has a supply of Avigan, sufficient to treat two million people.

Initially, the pharmaceutical company planned to complete the tests by the end of May but then extended the test period until the end of June. Yet, the company lacked 96 patients due to the drop in the number of new infections, according to the media outlet.

Japan has so fat confirmed 17,935 COVID-19 cases. A total of 932 people have died, 173 people are in serious condition. Over 15,000 patients have recovered.